TY  - JOUR
AU  - Alvarez-Roman, Maria Teresa
AU  - Benitez, Olga
AU  - Canaro, Maria Isabel
AU  - Lopez-Fernandez, Maria Fernanda
AU  - Lopez-Jaime, Francisco J
AU  - Mateo-Arranz, Jose
AU  - Nuñez, Ramiro
AU  - Rodriguez-Lopez, Manuel
AU  - Sierra-Aisa, Cristina
AU  - Jimenez-Yuste, Victor
PY  - 2021
DO  - 10.1080/14712598.2021.1932811
UR  - http://hdl.handle.net/10668/18164
T2  - Expert opinion on biological therapy
AB  - Introduction: Current guidelines recommend prophylactic treatment of hemophilia B with the missing coagulation factor IX, either with standard half-life or extended half-life products. Extended half-life products have half-lives three to six times...
LA  - en
PB  - Taylor & Francis
KW  - Albutrepenonacog alfa
KW  - Blood coagulation factors
KW  - Factor IX
KW  - Hemophilia B
KW  - Qualitative research
KW  - Expert Testimony
KW  - Factor IX
KW  - Half-Life
KW  - Hemophilia B
KW  - Humans
KW  - Quality of Life
KW  - Recombinant Fusion Proteins
KW  - Serum Albumin
TI  - Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa.
TY  - research article
VL  - 21
ER  -